Pilot Study of Vitamin K2 (MK-7) and Vitamin D3 Supplementation and the Effects on PASC Symptomatology and Inflammatory Biomarkers

NCT ID: NCT05356936

Last Updated: 2024-09-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 151 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-06-01
• Study Completion Date: 2024-08-01

Brief Summary

Participants are being asked to take part in this research study because they have had a previous diagnosis (at least 3 months ago) of COVID-19 and are experiencing persistent, recurrent or even new symptoms, i.e. post-acute sequelae of SARS-CoV-2 (PASC). The Investigators are interested in studying the effects of Vitamin K2 (MK-7) and Vitamin D3 supplementation on PASC symptoms and the underlying inflammatory process.

Conditions

Post-acute COVID-19 Syndrome

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Vitamin K2(MK-7) and Vitamin D3

Participants randomized to this group will receive Vitamin K2 (MK-7) and Vitamin D3 by mouth.

Group Type: EXPERIMENTAL

Vitamin K2 (MK-7)

Intervention Type: DIETARY_SUPPLEMENT

Participants will receive Vitamin K2 (MK-7) daily by mouth.

Vitamin D3

Intervention Type: DIETARY_SUPPLEMENT

Participants will receive Vitamin D3 daily by mouth.

Control

Participants to this group will receive no intervention.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Vitamin K2 (MK-7)

Participants will receive Vitamin K2 (MK-7) daily by mouth.

Intervention Type: DIETARY_SUPPLEMENT

Vitamin D3

Participants will receive Vitamin D3 daily by mouth.

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

• Previous COVID-19 infection as documented by a positive Nucleic Acid Amplification Test (NAAT) PCR test or any licensed SARS-CoV-2 antigen test kit and prolonged, recurrent or newly developed symptoms more than 3 months after the positive test result.
• Male or Female age ≥18 years
• Provides written informed consent and is capable of reading and comprehending the informed consent
• Able to swallow pills.
• No active nausea, vomiting
• All women of child-bearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to start of study medication. WOCBP is defined as any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), who is not postmenopausal (defined as amenorrhea for 12 consecutive months), or is on hormone replacement therapy (HRT) with documented plasma follicle-stimulating hormone level 35mLU/mL. Women who are using oral, implanted, or injectable contraceptive hormones or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy), should be considered to be of child bearing potential.
• Female subjects who are not of reproductive potential (have reached menopause or undergone hysterectomy, bilateral oophorectomy or tubal ligation) or whose male partner has undergone successful vasectomy with resulting azoospermia or has azoospermia for any other reason, are eligible without requiring the use of contraception. Acceptable documentation of menopause, sterilization, and azoospermia is patient reported history.
• All subjects must not participate in a conception process (e.g. active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization), and if participating in sexual activity that could lead to pregnancy, the female subject/male partner must use condoms (male or female) in addition to one of the following forms of contraception while on study: either a spermicidal agent, diaphragm, cervical cap, IUD, or hormonal-based contraception.

Exclusion Criteria

• Subjects unable to consent due to language barrier or cognitive impairment.
• Pregnancy/lactation.
• Regular use of agents that may affect inflammation in the last 3 months. The regular use of NSAIDS, aspirin, or statins will be allowed as long as dose has been stable for the last 3 months and is not expected to change during the study.
• Subject receiving vitamin K antagonists (e.g. warfarin, coumadin)
• Subject consuming supplements of vitamin K1, K2, or Vitamin D. A daily multivitamin will not be exclusionary as long as vitamin D is not > 600 UI daily.
• Presence of active neoplastic diseases requiring chemotherapy and/or use of immunosuppressive drugs
• BMI <18 kg/m2.
• Allergy or intolerance to vitamin K2 or vitamin D3
• Hospitalization within the previous 28 days.
• Inability or unwillingness of the individual to give written informed consent

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospitals Cleveland Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Grace McComsey

Vice President of Research

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Grace McComsey, MD, FIDSA

Role: PRINCIPAL_INVESTIGATOR

University Hospitals Cleveland Medical Center

Locations

University Hospitals Cleveland Medical Center

Cleveland, Ohio, United States

Countries

United States

Other Identifiers

STUDY20220109

Identifier Type: -

Identifier Source: org_study_id